Zinman B, et al. - In patients with inadequately controlled type 2 diabetes, researchers tested the safety and effectiveness of semaglutide when added to sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy. For this investigation, 302 subjects were recruited and randomly assigned to receive semaglutide 1·0 mg or placebo (full analysis set), of whom 301 received at least one dose of treatment (safety analysis set) between March 15, and December 4, 2017. According to this randomised, placebo-controlled trial, the addition of semaglutide to SGLT-2 inhibitor therapy significantly improves glycaemic control and decreases body weight in patients with inadequately controlled type 2 diabetes, and is generally well tolerated. The most common gastrointestinal adverse events were reported in 56 semaglutide patients and 20 patients in the placebo group.